Six clocks agreeing cuts against the chance this is one broken measurement tool. But 42 patients is still small, and disease-specific.
What it does is put aging biomarkers on the table as something a drug trial can move.
https://t.co/K1ivFuXzPy
The headline number: up to six years younger, biologically speaking.
That figure comes from Insilico's own reported results across six clocks, not from an outside lab, and there is no published paper backing it yet.
Insilico Medicine says a drug it designed with AI reversed biological aging markers in a 42-patient pulmonary fibrosis trial.
Six independent aging clocks showed drops of up to six years. Small trial. Company-reported. No peer review yet.
The trial was meant to test a treatment for pulmonary fibrosis, a scarring lung disease, and aging was never the original point, but researchers ran six separately built aging clocks on the same patients afterward anyway.
All six moved in the same direction.
The Trump administration filed a statement of interest backing OpenAI's fair use defense in The New York Times's copyright suit, The Verge reported.
It lands mid-trial. Both sides just filed summary judgment briefs, and a ruling could avoid trial entirely.
The same day, Seattle Times and Newsday filed their own suit over paywalled content feeding ChatGPT and Copilot.
Meanwhile AP and Vox Media chose licensing deals instead of court. Not everyone is litigating.
https://t.co/GYB2xkGNIY
Mistral AI has raised a EUR3 billion Series D at a post-money valuation of more than EUR21 billion, the company announced September 8. Samsung Electronics led the round.
It is Mistral's second straight round fronted by an industrial firm, not a financial one.
Mistral's pitch: open weights, private compute, auditable systems. No vendor lock-in.
That sovereignty framing is Mistral's own, laid out in the announcement with no independent assessment attached. Full story here:
https://t.co/Igx45ejenn
Dallas Fed economists tied a 2.6 percent drop in Texas job postings to generative AI exposure.
First-time job seekers absorbed most of the loss. Not workers already employed.
Unresolved: whether this holds nationally, whether the entry-level gap widens, whether the Dallas Fed publishes follow-up data confirming the link.
Full story here:
https://t.co/K1ivFuXzPy